Mirabutalebi Seyed Hamidreza, Karami Noorodin, Montazeri Fatemeh, Fesahat Farzaneh, Sheikhha Mohammad Hasan, Hajimaqsoodi Elnaz, Karimi Zarchi Mojgan, Kalantar Seyed Mehdi
Genetics Department, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Abortion Research Center, Yazd Reproductive Sciences Institute, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Int J Reprod Biomed. 2018 Aug;16(8):501-506.
The study of microRNA expression can be effective in the diagnosing and treating different diseases. miR-135a is one of the most important micro-ribonucleic acids involved in endometriosis. Among the genes that become the target of the miR-135a and are subjected to changes in the endometrium of patients with endometriosis is gene which is expressed in the endometrium in response to steroid hormones.
The aim of this study was to evaluate the expression of miR-135a and its relationship with the level of gene expression in both endometrial ectopic and eutopic tissues in patients with endometriosis compared to the control samples.
In this prospective case-control study, both case-eutopic and case-ectopic tissue samples were obtained from 17 women with endometriosis and the eutopic endometrial tissue was sampled from 17 women with normal endometrium as the control group. The gene's expression of miR-135a and were investigated using quantitative reverse transcription PCR (q-RT PCR).
A significant decrease in the expression of gene was detected in case-eutopic during the luteal phase compared to the control samples (p=0.001), while in the case-ectopic, the expression of this gene was increased (p=0.681) compared to the control samples. In addition, the expression miR-135a in the luteal phase showed a remarkable increase in the case-eutopic endometrial tissue (p=0.026) as well as a significant decrease in the case-ectopic endometrial tissue compared to the control samples (p=0.008).
Considering the inverse relations between the over-expression of miR-135a and the reduction of , it seems that miR-135a may be applied as an endometrial diagnostic and therapeutic biomarker.
微小RNA表达的研究在不同疾病的诊断和治疗中可能是有效的。miR-135a是参与子宫内膜异位症的最重要的微小核糖核酸之一。在成为miR-135a的靶标并在子宫内膜异位症患者的子宫内膜中发生变化的基因中,有一种基因在子宫内膜中响应类固醇激素而表达。
本研究的目的是评估miR-135a的表达及其与子宫内膜异位症患者子宫内膜异位组织和在位组织中该基因表达水平的关系,并与对照样本进行比较。
在这项前瞻性病例对照研究中,从17名子宫内膜异位症女性中获取病例在位组织样本和病例异位组织样本,并从17名子宫内膜正常的女性中获取在位子宫内膜组织作为对照组。使用定量逆转录PCR(q-RT PCR)研究miR-135a和该基因的表达。
与对照样本相比,在黄体期病例在位组织中检测到该基因的表达显著降低(p = 0.001),而在病例异位组织中,与对照样本相比该基因的表达增加(p = 0.681)。此外,与对照样本相比,黄体期miR-135a在病例在位子宫内膜组织中的表达显著增加(p = 0.026),而在病例异位子宫内膜组织中的表达显著降低(p = 0.008)。
考虑到miR-135a的过表达与该基因表达降低之间的负相关关系,似乎miR-135a可作为子宫内膜的诊断和治疗生物标志物。